Genetic Diseases
Conditions
Interventions
Warfarin genotyped group
Sponsors
Ilhaam Fredericks
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Age > 18 years old Patients who require warfarin anticoagulation as part of standard of care
Exclusion criteria
Exclusion criteria: Patients who do not have informed consent Patients with mechanical heart valves Patients who were anticoagulated with warfarin in the last 30 days Patients with liver failure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the time of reaching one therapeutic INR in patients whom warfarin is dosed with using point-of-care genotyping (Intervention Group) to time of reaching one therapeutic INR in patients where conventional warfarin dosing was used (Control Group). | — |
Secondary
| Measure | Time frame |
|---|---|
| To determine the incidence of supratherapeutic and subtherapeutic INR values in the Intervention Group compared with the Control Group. ;The number of times the warfarin dose is adjusted to achieve a therapeutic INR in the Intervention Group compared with the Control Group. ;To assess the incidence of adverse events related to warfarin in the Intervention Group compared with the Control Group. ;To compare the dosing recommendations of two internationally accepted dosing algorithms (the NHS warfarin dosing algorithm and the warfarindosing.org algorithm).;To assess the acceptability of warfarin POC genotype-guided dosing by clinicians. | — |
Countries
South Africa
Contacts
Public ContactIlhaam Fredericks
Internal Medicine Registrar
Outcome results
None listed